Skip to main content

Corporate leaders strive to make allyship a real thing at work

It has been a momentous year for tackling issues of social justice in the workplace—one that has seen those not directly impacted by issues of racial and gender inequality look to step up to the plate as allies to the cause.

But being an ally is easier said than done, and Fortune gathered a group of women well-versed in what it should mean and what it should look like to kick off the virtual, 2020 edition of the Most Powerful Women Summit on Thursday.

“Being a good ally is about taking concrete steps to turn your good intentions into actions,” Carin Taylor, chief diversity officer at Workday, said in her introductory remarks for the panel, entitled “Allyship and Accountability: It’s a Marathon, Not a Sprint.” Allyship, Taylor added, is about “taking a stand for those who may have a smaller voice” in a given organization and “driving equity for everyone.”

The three panelists, moderated by Fortune senior editor Ellen McGirt, further expounded on that idea and what good allyship entails, in a corporate environment and beyond. As Lindsay-Rae McIntyre, corporate vice president and chief diversity officer at Microsoft, noted, “there’s no amount of empathy and proximity that substitutes for lived experience”—which makes the task of being an ally all the more difficult for those who’ve never directly experienced race- or gender-based discrimination.

McIntyre stressed that it’s important to recognize allyship as “a behavior” and “something we work on every day” in the workplace, rather than “something performative” that people can claim to support without the actions to back it up.

Barbara Whye, chief diversity and inclusion officer and corporate vice president of social impact at Intel, echoed that sentiment.

“An ally is a partner that’s partnering with you for your good; we want someone that’s listening, that’s empathetic, someone that’s actionable,” Whye said. At the same time, Whye noted, it’s important to recognize that “allies are also discovering things about themselves and their own self-awareness on this journey that they’re on”—with allyship itself an experience that enables those of privilege to better learn and understand the challenges facing others.

At her own company, Whye said they’ve tried to “make sure every team inside Intel has a partner there, an ally that can ensure peoples’ ideas are being heard, and that there’s a safe environment for people.” And she echoed McIntyre in adding the importance of “being actionable, rather than just having conversations.”

“It’s best if other people call you an ally—you can’t self-proclaim it,” Whye added. “You’re deemed an ally by others, based on your actions and words.”

McIntyre said that at Microsoft, they’ve placed an emphasis on ensuring that efforts to promote allyship are not “intended to shame the source of the non-inclusive behavior.” While the company doesn’t tolerate “hateful, harmful behavior,” she noted it’s important to “invite folks into the allyship journey so that they can be self-aware” and develop positive habits, rather than being shamed for their previous non-inclusive actions.

McIntyre and Whye were also joined by author and activist Sophie Williams, whose books Millennial Black and Anti-Racist Ally—as well as her popular Instagram account—examine topics like anti-racist activism and the challenges facing women of color in the workplace and society at large. 

“My perspective has always been that we didn’t make this mess or these problems; it’s not realistic to tell us, ‘Here’s what you need to do,’ when the system was never made for us,” Williams said.

And while the work of fighting and organizing for social justice can be hard, tiresome, and thankless, Williams added that it’s important to understand that “you’re never going to see a quick fix” to many of the challenges and ills plaguing society—and that change is a long, arduous process that requires patience and perspective.

“Most people start this work knowing they’re never going to live to see the benefits,” she said. “We’re not doing it for us; we’re doing it for people other than us, the people who are marginalized by society.”

More on the most powerful women in business from Fortune:



from Fortune https://ift.tt/3kPWp5h

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be